The OPG/RANKL (osteoprotegerin/receptor activator of nuclear factor kappa-B) system, which plays a crucial role in bone metabolism, is also associated with vascular calcification. Acromegaly is characterized by excessive secretion of growth hormone and insulin-like growth factor, and studies have demonstrated an elevated risk of cardiovascular disease in individuals with acromegaly. In this study, our objective was to investigate the relationship between OPG/RANKL and various cardiovascular risk scoring systems.
We recruited 44 consecutive acromegaly patients and 41 healthy controls with a similar age and gender distribution for this study.
While RANKL levels were significantly higher in the acromegaly group compared to the controls, OPG levels were not found to be significantly different between the two groups. Furthermore, within the acromegaly group, RANKL levels were significantly higher in patients with active acromegaly compared to those with controlled acromegaly.
Osteoprotegerin levels showed a positive correlation with the Framingham risk score (FRS) in the acromegaly group. Linear regression analysis revealed an association of OPG with FRS (adjusted R2 value of 21.7%).
OPG and RANKL may serve as potential markers for assessment of cardiovascular calcification and prediction of the cardiovascular risk status in acromegalic patients.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Zhang L, Zeng F, Jiang M, Han M, Huang B (2022) Roles of osteoprotegerin in endocrine and metabolic disorders through receptor activator of nuclear factor kappa-B ligand/receptor activator of nuclear factor kappa-B signaling. Front Cell Dev Biol 10:1005681. https://doi.org/10.3389/fcell.2022.1005681
Monseu M, Dubois S, Boursier J, Aube C, Gagnadoux F, Leftheriotis G, Ducluzeau PH (2016) Osteoprotegerin levels are associated with liver fat and liver markers in dysmetabolic adults. Diabetes Metab 42:364–367. https://doi.org/10.1016/j.diabet.2016.02.004
Harper E, Forde H, Davenport C, Rochfort KD, Smith D, Cummins PM (2016) Vascular calcification in type-2 diabetes and cardiovascular disease: Integrative roles for OPG, RANKL and TRAIL. Vascul Pharmacol 82:30–40. https://doi.org/10.1016/j.vph.2016.02.003
Callegari A, Coons ML, Ricks JL, Yang HL, Gross TS, Huber P, Rosenfeld ME, Scatena M (2013) Bone marrow- or vessel wall-derived osteoprotegerin is sufficient to reduce atherosclerotic lesion size and vascular calcification. Arterioscler Thromb Vasc Biol 33:2491–2500. https://doi.org/10.1161/ATVBAHA.113.301755
Harsha MM, Tewari S, Gupta SK, Khanna R, Kumar S, Garg N, Kapoor A, Goel PK (2021) Acromegaly: cardiovascular risk factors, cardiovascular manifestations and early vascular alterations in relation to disease activity. Indian Heart J 73:499–502. https://doi.org/10.1016/j.ihj.2021.05.005
Rubin J, Ackert-Bicknell CL, Zhu L, Fan X, Murphy TC, Nanes MS, Marcus R, Holloway L, Beamer WG, Rosen CJ (2002) IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo. J Clin Endocrinol Metab 87:4273–4279. https://doi.org/10.1210/jc.2002-020656
Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA, Endocrine S (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:3933–3951. https://doi.org/10.1210/jc.2014-2700
Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847. https://doi.org/10.1161/01.cir.97.18.1837
Lloyd-Jones DM, Huffman MD, Karmali KN, Sanghavi DM, Wright JS, Pelser C, Gulati M, Masoudi FA, Goff DC Jr (2017) Estimating longitudinal risks and benefits from cardiovascular preventive therapies among medicare patients: the Million Hearts Longitudinal ASCVD Risk Assessment Tool: a special report from the American Heart Association and American College of Cardiology. J Am Coll Cardiol 69:1617–1636. https://doi.org/10.1016/j.jacc.2016.10.018
Ulloque-Badaracco JR, Hernandez-Bustamante EA, Alarcon-Braga EA, Mosquera-Rojas MD, Campos-Aspajo A, Salazar-Valdivia FE, Valdez-Cornejo VA, Benites-Zapata VA, Herrera-Anazco P, Valenzuela-Rodriguez G, Hernandez AV (2022) Atherogenic index of plasma and coronary artery disease: a systematic review. Open Med (Wars) 17:1915–1926. https://doi.org/10.1515/med-2022-0590
Ozer FF, Dagdelen S, Erbas T (2018) Relation of RANKL and OPG levels with bone resorption in patients with acromegaly and prolactinoma. Horm Metab Res 50:562–567. https://doi.org/10.1055/a-0630-1529
Zhao HY, Liu JM, Ning G, Zhao YJ, Chen Y, Sun LH, Zhang LZ, Xu MY, Chen JL (2008) Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women. Osteoporos Int 19:221–226. https://doi.org/10.1007/s00198-007-0440-y
Constantin T, Tangpricha V, Shah R, Oyesiku NM, Ioachimescu OC, Ritchie J, Ioachimescu AG (2017) Calcium and bone turnover markers in acromegaly: a prospective, controlled study. J Clin Endocrinol Metab 102:2416–2424. https://doi.org/10.1210/jc.2016-3693
Jawiarczyk-Przybylowska A, Halupczok-Zyla J, Syrycka J, Zembska A, Kuliczkowska-Plaksej J, Bolanowski M (2022) Trabecular bone score and osteoprotegerin as useful tools in the assessment of bone deterioration in acromegaly. Front Endocrinol (Lausanne) 13:862845. https://doi.org/10.3389/fendo.2022.862845
Goluke NMS, Schoffelmeer MA, De Jonghe A, Emmelot-Vonk MH, De Jong PA, Koek HL (2022) Serum biomarkers for arterial calcification in humans: a systematic review. Bone Rep 17:101599. https://doi.org/10.1016/j.bonr.2022.101599
Rochette L, Meloux A, Rigal E, Zeller M, Cottin Y, Vergely C (2019) The role of osteoprotegerin and its ligands in vascular function. Int J Mol Sci 20:705. https://doi.org/10.3390/ijms20030705
Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102–152. https://doi.org/10.1210/er.2002-0022
Orme SM, McNally RJ, Cartwright RA, Belchetz PE (1998) Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 83:2730–2734. https://doi.org/10.1210/jcem.83.8.5007
Bogazzi F, Battolla L, Spinelli C, Rossi G, Gavioli S, Di Bello V, Cosci C, Sardella C, Volterrani D, Talini E, Pepe P, Falaschi F, Mariani G, Martino E (2007) Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J Clin Endocrinol Metab 92:4271–4277. https://doi.org/10.1210/jc.2007-1213
Akutsu H, Kreutzer J, Wasmeier G, Ropers D, Rost C, Mohlig M, Wallaschofski H, Buchfelder M, Schofl C (2010) Acromegaly per se does not increase the risk for coronary artery disease. Eur J Endocrinol 162:879–886. https://doi.org/10.1530/EJE-09-0945
Greenland P, Bonow RO, Brundage BH, Budoff MJ, Eisenberg MJ, Grundy SM, Lauer MS, Post WS, Raggi P, Redberg RF, Rodgers GP, Shaw LJ, Taylor AJ, Weintraub WS, American College of Cardiology Foundation Clinical Expert Consensus Task F, Society of Atherosclerosis I, Prevention, Society of Cardiovascular Computed T (2007) ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography) developed in collaboration with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol 49:378–402. https://doi.org/10.1016/j.jacc.2006.10.001
Arad Y, Goodman KJ, Roth M, Newstein D, Guerci AD (2005) Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study. J Am Coll Cardiol 46:158–165. https://doi.org/10.1016/j.jacc.2005.02.088
Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC (2004) Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA 291:210–215. https://doi.org/10.1001/jama.291.2.210
Ragonese M, Alibrandi A, Di Bella G, Salamone I, Puglisi S, Cotta OR, Torre ML, Ferrau F, Ruggeri RM, Trimarchi F, Cannavo S (2014) Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction. Endocrine 47:206–212. https://doi.org/10.1007/s12020-013-0115-8
Semb AG, Ueland T, Aukrust P, Wareham NJ, Luben R, Gullestad L, Kastelein JJ, Khaw KT, Boekholdt SM (2009) Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993–2003. Arterioscler Thromb Vasc Biol 29:975–980. https://doi.org/10.1161/ATVBAHA.109.184101
Venuraju SM, Yerramasu A, Corder R, Lahiri A (2010) Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol 55:2049–2061. https://doi.org/10.1016/j.jacc.2010.03.013
This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committe of Izmir Bozyaka Training and Research Hospital. The patients gave oral and written informed consent before recruitment (ethics approval number 7, date 24 December 2013).
Conflict of interest
The authors declare no competing interests.
Gokcen Unal Kocabas is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
About this article
Cite this article
Kocabas, G.U., Yurekli, B.S., Simsir, I.Y. et al. Assessment of osteoprotegerin and RANKL levels and several cardiovascular risk scoring systems in acromegaly. Hormones (2023). https://doi.org/10.1007/s42000-023-00509-8